Category: 3. Business

  • STM bus drivers, metro operators, station agents and paratransit drivers vote for tentative agreement!

    STM bus drivers, metro operators, station agents and paratransit drivers vote for tentative agreement!

    A majority of CUPE 1983 members in Montreal voted in favour of the tentative agreement presented at two general meetings held on December 14, 2025. CUPE 1983 represents the 4,500 bus drivers, metro operators, station agents and paratransit drivers at the Société de transport de Montréal (STM). The vote came after the members’ seven-day analysis of the proposed agreement.

    Planned salary increases total 17.5% for the duration of the collective agreement, which breaks down to 2.5% in 2025, 4.5% in 2026, 3.25% in 2027 and 2028, and 4% in 2029, plus a lump sum of 2.5% for 2025. Other negotiated gains include the creation of a cumulative bank of hours as well as the addition of recovery times on short lines, service-hour payment and more flexibility for work-life balance.

    The union president thanked the participants in the public debate, who opted for a negotiated agreement rather than playing the government’s game that was supported by Montréal mayor Soraya Martinez Ferrada and Québec solidaire deputy Alexandre Leduc.

    He also reiterated that, while the union is satisfied with the outcome of this round of bargaining, the fight is not over for an adequately funded public transit network that would lead to a true and just transition. CUPE 1983 will continue its involvement, particularly to fight the privatization of the STM’s paratransit service.

    “Underfunding is the crux of the problem,” said the president of CUPE 1983. “Until the key decision-makers make public transit a priority, we’re doomed to see history repeat.”

    Continue Reading

  • Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

    New Brunswick, N.J., December 15th, 2025 Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.

    Investors and other interested parties can access the webcast/conference call in the following ways:

    • The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
    • By telephone: for both “listen-only” participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
    • A replay of the conference call will be available until approximately 12:00 a.m. on February 4th. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13757287.
    • The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.
    • Please refer to www.investor.jnj.com for a complete list of currently planned earnings webcast/conference calls.Please note the first-quarter date of Tuesday, April 14th, 2026.

    About Johnson & Johnson
    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. 


    Continue Reading

  • The request could not be satisfied


    ERROR: The request could not be satisfied

    The request could not be satisfied.


    Request blocked.
    We can’t connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner.


    If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.


    Generated by cloudfront (CloudFront)
    Request ID: d4JhOdr-A93uB7E4AfedfnV5nA1x-ueo90A4W5Dx8-Cc9JKmv7CHiw==
    

    Continue Reading

  • U.S. Legislation Subjects Directors and Officers of Foreign Private Issuers to Section 16(a) Reporting Obligations | Insights

    On December 10, 2025, the U.S. House of Representatives passed the National Defense Authorization Act for Fiscal Year 2026 (the NDAA). The NDAA is a broad policy bill that authorizes spending levels, policies, and authorities for key military and national security activities for the upcoming fiscal year. However, buried within the sweeping legislation is Section 8103, Disclosures by Directors, Officers, and Principal Stockholders, or the Holding Foreign Insiders Accountable Act (the HFIAA). Under the HFIAA, Section 16(a) of the Securities Exchange Act of 1934 (the Exchange Act) will be amended to subject directors and officers of foreign private issuers (FPIs) to the Securities and Exchange Commission (SEC) reporting requirements on Forms 3, 4, and 5. 

    The NDAA is now headed to the Senate for approval, which is expected to happen prior to the upcoming holiday break. The amendments under the NDAA will take effect 90 days after it is signed into law.

    Key Requirements of Section 16(a) of the Exchange Act

    Section 16(a) of the Exchange Act requires directors, officers, and 10% beneficial owners (collectively, insiders) of a public company’s listed equity securities to publicly report their ownership and transactions in such public company’s securities. These insiders are required to report their initial ownership in the public company’s equity securities on SEC Form 3 in connection with an initial public offering by the date the registration statement becomes effective or, for already public companies, within 10 calendar days of becoming a reporting person under Section 16. In addition, these insiders are required to report subsequent transactions in the public company’s equity securities (e.g., purchases and sales, gifts, and compensation-related transactions, including equity compensation grants and other transactions in connection with such equity compensation grants) on SEC Form 4 within two business days of the relevant transaction. They must also report annually certain other transactions that were not reported on either SEC Forms 3 or 4, on SEC Form 5 within 45 days of the public company’s fiscal year end.

    Violations of Section 16(a)

    Late or missing filings of Section 16 reports constitute a violation of the securities laws by the individual responsible for making the filing and can draw SEC scrutiny to the FPI, particularly in cases where there are multiple or frequent violations. The SEC has recently focused on untimely filings of Section 16 reports, announcing last year several enforcement actions against individuals – and the affiliated public companies that had undertaken to file on their behalf – for failure to timely file Section 16 reports. The SEC ultimately has broad authority to enforce the securities laws and is permitted to seek “any equitable relief that may be appropriate or necessary for the benefit of investors.” 

    Impact on FPIs: Additional Transparency for Equity Ownership and Compensation

    Historically, insiders of FPIs were exempt from the Section 16(a) reporting requirements, the Section 16(b) short-swing disgorgement rules, and the Section 16(c) short-sale restrictions, each of which apply to insiders of U.S. domestic public companies. While the NDAA does not go so far as to subject FPIs to Section 16(b) (for short-swing profit liability) or 16(c) (for short-sale restrictions), directors and officers of FPIs will soon be required to report changes in their individual beneficial ownership, including any equity compensation awards received. The NDAA does not, however, extend Section 16(a) reporting requirements to 10% beneficial owners of FPIs.  

    More broadly, FPIs have historically not been required to report the individual compensation of their directors and officers unless such disclosure was required to be made in their home country, and an individual’s equity ownership in the FPI was not required to be disclosed unless it exceeded 1% of the FPI’s total outstanding class of shares. In many cases, equity compensation represents a significant portion of an officer’s overall compensation from a company, and, via Section 16 reporting, such compensation will now be made publicly available. For many insiders, this will represent the first time they need to publicly disclose their individual shareholdings.

    The HFIAA does include a new provision that allows the SEC the authority to exempt any person, security, or transaction from Section 16 reporting obligations if the SEC determines that the laws of a foreign jurisdiction apply “substantially similar requirements” to such person, security, or transaction. However, it is not clear what “substantially similar” means or how likely it will be that the SEC grants such an exemption.

    Key Considerations

    These changes represent a significant departure for the way FPIs report director and officer compensation and will create new filing obligations for directors and officers of FPIs. Below are a few key points to consider in connection with the implementation of the HFIAA:

    • FPIs should revisit who they have designated as “executive officers” in their disclosure and in connection with the adoption of their clawback policies as those same officers will now be subject to the above Section 16 reporting requirements.
    • FPIs should start to prepare for the implementation of these reporting requirements by enrolling their directors and officers in EDGAR Next, to the extent they are not already enrolled for purposes of electronically filing Forms 144, to ensure each director and officer is appropriately set up to make filings with the SEC.

    Continue Reading

  • Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

    Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

    GSK plc (LSE/NYSE: GSK) today announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications:

    • as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids (ICS) plus another asthma controller;
    • as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.

    The approval is based on data from the SWIFT and ANCHOR phase III trials which showed sustained efficacy with a twice-yearly dosing regimen for depemokimab. Each of the four trials met their primary or co-primary endpoints with statistically significant and clinically meaningful results, comparing the addition of depemokimab to standard of care versus standard of care alone.1,2

    Kaivan Khavandi, SVP & Global Head, Respiratory, Immunology & Inflammation R&D, GSK said: “Today’s UK approval of Exdensur, the first in the world, has the potential to redefine care for millions of patients. This ultra-long-acting biologic delivers sustained efficacy to reduce asthma exacerbations, keep patients out of hospital and help prevent cumulative lung damage in just two doses a year. This is a step change in respiratory treatment, and we look forward to additional regulatory decisions expected in the US, Japan, EU and China.”

    Asthma affects more than 260 million people globally3 and about 7 million people in the UK,4 a portion of whom have type 2 inflammation characterised by an eosinophilic phenotype.5 Approximately half continue to experience symptoms and exacerbations despite treatment.6 Asthma exacerbations place a significant resource burden on healthcare systems due to emergency department visits and hospitalisations, with an estimated 22% increase in NHS costs by 2031.7 With the potential to reduce asthma exacerbations, including those leading to hospitalisations, and alleviate the debilitating symptoms associated with CRSwNP, Exdensur could improve patient outcomes while contributing to a reduction in health system burden.

    The pooled results from the SWIFT trials showed a 54% reduction in clinically significant exacerbations (asthma attacks) over 52 weeks [rate ratio 0.46, 95% confidence interval (0.36, 0.59), nominal p<0.001] (AER depemokimab = 0.51 exacerbations per year versus placebo = 1.11).1 Additionally, this pooled analysis showed a 72% reduction [RR 0.28, 95% CI (0.13, 0.61), nominal p=0.002] (AER: depemokimab = 0.02 versus placebo = 0.09) in the secondary endpoint of clinically significant exacerbations requiring hospitalisation or emergency department visit compared to placebo.1 In AGILE, an open-label 12-month extension study, depemokimab maintained the results seen in SWIFT-1 and SWIFT-2, confirming the sustained safety and efficacy of a twice-yearly dose of depemokimab over the course of two years.

    Pooled results from the ANCHOR trials showed an improvement (reduction) from baseline in nasal polyp score (scale: 0-8) at 52 weeks [treatment difference -0.7, 95% CI (-0.9, -0.4), nominal p<0.001] and in nasal obstruction verbal response scale (scale: 0-3) over weeks 49-52 [treatment difference -0.24, 95% CI (-0.39, -0.08), nominal p=0.003].2

    Across these trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo.1,2

    Depemokimab recently received a positive CHMP opinion in the EU and it is currently under regulatory review in other countries, including in the US, Japan and China. Decisions on these approvals are expected starting in December 2025 and continuing through H1 2026.

    About asthma with type 2 inflammation

    Asthma affects more than 260 million people globally, many of whom continue to experience symptoms and exacerbations despite treatment.8,9 Severe asthma is defined as asthma that requires treatment with medium- to high-dose inhaled corticosteroids plus a second therapy (i.e., systemic corticosteroid or biologic) to prevent it from becoming uncontrolled, or which remains uncontrolled despite therapy.10 Type 2 inflammation is the underlying cause of pathology in more than 80% of patients with severe asthma, in which patients exhibit elevated levels of eosinophils (a type of white blood cell).11

    About CRSwNP

    CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps.12,13 People with CRSwNP experience debilitating symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being.12,13 Similar to asthma, the majority of cases of CRSwNP (85%) are driven by chronic type 2 inflammation, which is strongly associated with comorbidities, more severe disease, recurring symptoms and tissue remodelling.14

    About Exdensur (depemokimab)

    Exdensur is the first ultra-long-acting biologic being evaluated for certain respiratory diseases with underlying type 2 inflammation, such as severe asthma. It combines high interleukin-5 (IL-5) binding affinity and high potency with an extended half-life to enable twice-yearly dosing.1 IL-5 is a key cytokine in type 2 inflammation.

    More information can be found in the Exdensur Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.

    About the SWIFT phase III trials

    Results from the SWIFT trials were presented at the 2024 European Respiratory Society International Conference and published in the New England Journal of Medicine.

    The SWIFT-1 and SWIFT-2 clinical trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 participants with severe asthma who were randomised to receive depemokimab or a placebo respectively, in addition to their standard of care (SOC) treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller. The full analysis set in SWIFT-1 included 250 patients in the depemokimab plus SOC arm and 132 in the placebo plus SOC arm; in SWIFT-2, 252 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm.1

    About the ANCHOR phase III trials

    Results from the ANCHOR trials were presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and published in The Lancet.

    ANCHOR-1 included 143 patients in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm; in ANCHOR-2, 129 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm.

    All 528 patients had inadequately controlled CRSwNP, including nasal polyps in both nasal cavities (an endoscopic bilateral NPS ≥5), and had either undergone previous surgery for CRSwNP, had received previous treatment with SCS or were intolerant to SCS. Patients received depemokimab or placebo at six-monthly intervals (26 weeks) in addition to SOC (maintenance intranasal corticosteroids).2

    About the depemokimab development programme

    Depemokimab is currently being evaluated in phase III trials for the treatment of other diseases with underlying type 2 inflammation, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA) and DESTINY for hyper eosinophilic syndrome (HES). GSK has also initiated the ENDURA-1, ENDURA-2 and VIGILANT phase III trials assessing the efficacy and safety of depemokimab as an add-on therapy in patients with uncontrolled moderate to severe COPD with type 2 inflammation.

    About GSK in respiratory

    GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression.

    Continue Reading

  • Field Notes: Where AI meets learning in Moodle LMS

    Field Notes: Where AI meets learning in Moodle LMS

    At Moodle, we’ve always believed that great learning design starts with people. Technology should enhance learning and make it more engaging, memorable and effective. This is the idea behind our approach to AI. We build technology tools to serve human goals, not replace them.

    Across the Moodle community, we’re seeing educators and organisations explore AI in ways that fit their own context, whether that is saving time, sparking ideas, or making everyday teaching and learning a little smoother. But we also know that not everyone wants, or can rely on, AI tools. And we’re building for them, too.

    Moodle LMS exists to make learning available to everyone — regardless of location, financial situation, or access to basic resources like electricity and the internet. Because this is part of our mission, we cannot make core LMS capability dependent on AI.

    Marie Achour, Chief Product Officer

    That’s why we’ve built AI in Moodle LMS around a clear set of principles — grounded in choice, privacy, and people-first learning — giving you the freedom to use AI when and how it supports your goals (including not using AI, if that’s what works best for your learners).

    Continue Reading

  • Privacy in the House: Remarks at the Privacy and Financial Surveillance Roundtable

    Thank you, Chairman Atkins, Commissioner Uyeda, and Richard. And thank you all for joining us in-person or online for the Crypto Task Force’s sixth roundtable. Thank you especially to our moderator, Yaya Fanusie, and today’s panelists for what will be an interesting and perhaps passionate discussion about financial surveillance and privacy.

    Happy Bill of Rights Day![i] Last time when I spoke at length about privacy, I told the story of my grandfather and his not-so-private telephone conversation.[ii] My other grandfather lived across the ocean in Friesland, which is in the northern part of the Netherlands. During the Nazi occupation of the country, a German officer came to my grandfather’s house to secure a room for the officer’s girlfriend. My grandfather, an opponent of the occupiers, certainly could not have one of them living in his house. So, my mother, who was a young child, was paraded in front of the officer with a warning that the house was full of similarly runny-nosed children. Wouldn’t his girlfriend prefer to live somewhere else? She would, and the family was spared a spy in their midst. Even in less dire times when the stakes are lower, the idea of having an uninvited stranger in your house, watching everything you do, is unthinkable. In this country, people have an expectation of privacy in their homes; the law sets up barriers to prevent government surveillance of people suspected of no wrongdoing.

    Similar expectations and protections of privacy do not exist for our financial lives. The lack of financial privacy is puzzling. After all, a walk through someone’s financial transactions will tell the government as much or more about someone as would a walk through her home. Legal developments, most notably the third-party doctrine, and the decades-long cultivation of an anti-financial-privacy ethos in our national consciousness have made mass surveillance routine when it comes to the financial system. People assume—often correctly—that the government is watching their financial transactions and shrug it off because they “have nothing to hide.”

    Our national degradation of financial privacy and the rules that embody it are overdue for a change, and crypto is helping to nudge a reassessment. On the one hand, crypto opens new possibilities for transactions without the financial intermediaries that are central to existing financial surveillance programs. Tokenized securities transactions, for example, can occur without the intermediation of a broker. As our personal transactions become increasingly disintermediated, government will receive less information about those transactions from traditional channels. On the other hand, the public blockchains on which many crypto transactions take place are viewable by everyone, which creates a demand for privacy-protecting tools. Accordingly, as crypto usage increases, the public and relevant government agencies need to rethink when and how financial transactions are surveilled.

    Deep thought about financial surveillance and privacy issues as they relate to cryptocurrencies is not new. Some of our panelists and others like Ian Miers and Matthew Greene have been thinking about these issues for many years, but new technological developments are broadening the conversation. Accordingly, the recently passed GENIUS Act, which regulates centralized stablecoins, directs Treasury “to identify innovative or novel methods, techniques, or strategies that regulated financial institutions use, or have the potential to use, to detect illicit activity, such as money laundering, involving digital assets . . . .”[iii] That process is underway.[iv] Also in-process are efforts to develop tools to enable law-abiding citizens to live private lives and protect themselves from bad actors. Zero-knowledge proofs shield private information while proving, for example, that someone is permitted to conduct a given transaction. Mixers enable people to make charitable donations,[v] get paid, lend money to a friend, or engage in other legal transactions without telegraphing them to the world. Decentralized physical infrastructure networks provide essential services without a central actor who can withhold these services from disfavored people. At today’s roundtable, we will hear about these and other new technologies designed to protect the privacy of transactions occurring on blockchains and to streamline compliance. The SEC does not endorse any particular product but understanding how these technologies work will inform policymakers as they seek to address the threats facing this nation without undermining our civil liberties.

    Several themes should guide the government’s work. Government should not assume ill-intent when people take steps to guard their privacy. Protecting one’s privacy should be the norm, not an indicator of criminal intent. Government should resist the temptation to force intermediation for the purpose of creating a regulatory beachhead or facilitating financial surveillance. Relatedly, the government should avoid imposing regulatory obligations, including Bank Secrecy Act obligations, on a software developer who does not have custody of users’ assets or the ability to override users’ choices.[vi] Additionally, the government should pursue bad actors who use privacy-protecting tools for nefarious purposes while protecting good actors who develop and publish these tools and the law-abiding citizens’ who use them to protect themselves from bad actors.

    I look forward to hearing builders and policy professionals on today’s panels discuss how we can use new technologies to protect this nation and to preserve the liberties that make it so special, including the freedom to live a private life. What better day to have this conversation than today, Bill of Rights Day.
     

    Continue Reading

  • Hartford Hospital Named Top Teaching Hospital | Hartford Hospital

    Hartford Hospital Named Top Teaching Hospital | Hartford Hospital

    << Back

    December 15, 2025

    Highlighting its nationally recognized achievements in patient safety and quality, Hartford Hospital has been named a Top Teaching Hospital, now five years in a row, by The Leapfrog Group, a national watchdog organization for health care safety and quality. This award is widely acknowledged as one of the most competitive awards American hospitals can receive.

    “This recognition, five years in a row, is one way to underscore the value of putting the patient at the center of everything we do,” said Cheryl Ficara, RN, MSN, NEA-BC, President of Hartford Hospital and Senior Vice President of Hartford HealthCare. “As a high reliability organization, we take error prevention very seriously. I commend our colleagues for upholding rigorous standards in every interaction and am proud of the critical work our team members do every day. This award highlights Hartford Hospital’s national standing as a place to receive and provide care.”

    Only 73 hospitals in the country received the Top Teaching award this year.

    The Leapfrog Group rates hospitals on how well they protect patients from preventable harm, including accidents, injuries and infections. The Leapfrog Top Teaching Hospital award is given to hospitals that publicly report their performance through the Leapfrog Hospital Survey and meet the high standards defined in the Top Hospitals methodology. This includes infection rates, maternity care and a hospital’s ability to prevent medication errors, among other standards. The rigorous standards are defined in each year’s Top Hospital Methodology.

    To qualify for the distinction, hospitals must rank top among peers on the Leapfrog Hospital Survey, which assesses hospital performance on the highest standards for quality and patient safety, and achieve top performance in their category.

    Continue Reading

  • Bexar County Medical Examiner seeks public’s help to identify man’s body found on West Side

    Bexar County Medical Examiner seeks public’s help to identify man’s body found on West Side

    The man’s body was found at 6808 Northwest Loop 410 on June 24

    RENDERING – The man’s body was found at 6808 Northwest Loop 410 on June 24 (Bexar County Medical Examiner)

    SAN ANTONIO – The Bexar County Medical Examiner’s Office is asking for the public’s help to identify a person whose body was found in June on the West Side.

    After exhausting all investigative avenues, the ME’s office said it is working to identify a white male who was approximately 70 to 80 years old. He was approximately 5 feet, 1 inch tall.

    The man was found on June 24 at 6808 NW Loop 410 in San Antonio.

    Anyone who recognizes the individual in the sketch is asked to contact the investigative section of the ME’s office at 210-335-4011.

    View more unsolved cases here.

    ALSO ON KSAT.COM


    Continue Reading

  • Department of Labor & Workforce Development

    December 15, 2025

    TRENTONInvestigators from the New Jersey Department of Labor and Workforce Development’s (NJDOL) Division of Wage and Hour Compliance issued the following stop-work order on December 3, 2025: 

    Employer: All American Drywall LLC of Jersey City, N.J. (subcontractor)
    Work Locations: Three sites in Jersey City, N.J. – 25 Cottage Street, 35 Cottage Street, and 10 Journal Square.
    Nature of Work: Construction maintenance
    Details: All American Drywall LLC was hired to the three projects in the Journal Square neighborhood by primary contractor A.J.D. Construction Co. Inc. of Leonardo, N.J. NJDOL previously issued stop-work orders to four other subcontractors working at 10 Journal Square Plaza earlier this year.
    Violations: Improper classification of construction workers; failing to properly classify employees; not paying overtime; unpaid wages/late payment; no Earned Sick Leave records; Earned Sick Leave notification/posting violations; and hindrance/failure to provide records.
    Workers Affected: 53 

    NJDOL has issued 211 stop-work orders since these powers were expanded in July 2019. 

    Stop-work orders are initiated by NJDOL to halt work being performed in a manner that exploits workers, or is otherwise noncompliant with state laws and regulations. An employer may appeal a stop-work order, in which case NJDOL has seven days to schedule a hearing. 

    NJDOL continues to monitor locations where stop-work orders have been issued, and can assess civil penalties of $5,000 per day against an employer conducting business in violation of the order. The stop-work order may be lifted if and when any remaining back wages and penalties have been paid and all related issues have been resolved. 

    For more information on worker benefits and protections, please visit myworkrights.nj.gov. 

    Go back to all press releases

    Continue Reading